PDLGG, a new category in the WHO CNS tumors classification 2021, comprises four tumors showing MYB/MYBL1 fusion with a partner gene or MAPK pathway activating mutations involving primarily BRAF or FGFR1. However, this classification is still in its early stages and presents some confusion. This evidence concerns the gene BRAF and central nervous system neoplasm.